News from IAS 2009

The perils of success: what if the new HIV prevention methods work?
Friday, September 04, 2009, by Gus Cairns
Filed under: Conference news, Women and HIV news, Prevention news, Microbicides news, IAS 2009

Within a couple of years’ time, we may know if two crucial new HIV prevention approaches will work. If they do, what then? Who will pay for them, who will use them, and will their use have a positive or negative impact on the epidemic? A debate at the International AIDS Society (IAS) Conference in Cape Town in July, sponsored by the IAS and the AIDS Vaccine Advocacy Coalition (AVAC) looked at how to prepare for microbicides and pre-exposure prophylaxis (PrEP).

Vaginal washing increases HIV infection risk; results for dry sex less clear-cut
Thursday, July 30, 2009, by Roger Pebody
Filed under: Africa news, Women and HIV news, Conference news, IAS 2009, Prevention news

A meta-analysis of data on vaginal practices and HIV infection from ten African cohorts has found that both vaginal washing with soap and wiping the vagina with cloths, tissues or paper were associated with an increased risk of acquiring HIV, researchers reported at the Fifth International AIDS Society conference in Cape Town last week. The use of products to dry or tighten the vagina, often referred to as ‘dry sex’, did not however have a statistically significant association with HIV infection.

Nevirapine matches atazanavir/ritonavir in 48-week study
Wednesday, July 29, 2009, by Keith Alcorn
Filed under: Conference news, Starting treatment news, IAS 2009

Nevirapine has equivalent efficacy to atazanavir/ritonavir when combined with tenofovir and FTC in treatment-naive patients, results from the ARTEN study show.

Genotypic tests matches tropism test in predicting who benefits from CCR5 inhibitors
Tuesday, July 28, 2009, by Keith Alcorn
Filed under: Medical tests news, Starting treatment news, Conference news, IAS 2009

A genotypic test is just as accurate as a more expensive tropism test in determining which treatment-experienced patients are suitable for treatment with the CCR5 inhibitor maraviroc, researchers from the University of British Columbia reported at the Fifth International AIDS Society conference in Cape Town last week.

Hepatitis B vaccine scale-up and treatment of HIV/HBV co-infection present challenges
Tuesday, July 28, 2009, by Liz Highleyman
Filed under: Hepatitis news, Conference news, IAS 2009

Hepatitis B vaccine coverage has increased dramatically in recent years, but some regions still lag behind and collaboration with broader health programmes would aid scale-up, according to a symposium presentation on viral hepatitis at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Cape Town, South Africa.

Aidsmap news coverage

Aidsmap.com brings you all the latest HIV news all year round.

If you would like to get a regular round-up of the latest news direct to your inbox, sign up for our email bulletins.

If you would like to add aidsmap.com news stories to your website, you can use our RSS feed.

Clinical Care Options

Clinical Care Options were also an official partner for IAS 2009, providing:

  • Capsule Summaries
  • Audio Podcasts
  • Expert Analyses
  • Downloadable PowerPoint Slides

Visit their website for more information.

Donate